BioTime owns, controls or has licensed directly, or through our subsidiaries, over 700 patents and pending patent applications worldwide, including more than 340 issued or allowed U.S. patents. We also own or control over 210 pending U.S. patent applications, including provisional patent applications, to protect our proprietary technologies.
Our patents and patent applications are directed to stem cells, cells derived from stem cells, methods of culturing and differentiating stem cells, regenerative medicine and tissue engineering. Our patents and patent applications cover compositions of matter, formulations, and methods of use and/or methods of manufacturing, as appropriate. A partial listing of the cell types that BioTime’s patents are directed towards include: